Details of Disease

Disease Name

Ductal breast carcinoma in situ

breast ductal carcinoma in situ; non-infiltrating intraductal adenocarcinoma of breast; ductal carcinoma in situ of breast; ductal carcinoma in situ (DCIS); non-infiltrating ductal breast carcinoma; non-invasive intraductal breast adenocarcinoma; intraductal carcinoma of the breast; intraductal carcinoma of breast; DCIS; non-infiltrating ductal carcinoma of the breast; non-infiltrating ductal adenocarcinoma of the breast; non-invasive ductal adenocarcinoma of breast; ductal breast carcinoma in situ; non-infiltrating ductal adenocarcinoma of breast; non-infiltrating ductal carcinoma of breast; ductal carcinoma in situ; non-infiltrating intraductal breast adenocarcinoma; non-infiltrating ductal breast adenocarcinoma; stage 0 mammary duct carcinoma; mammary duct in situ carcinoma; carcinoma in situ of mammary duct; non-infiltrating intraductal carcinoma; non-invasive intraductal adenocarcinoma of the breast; non-invasive ductal carcinoma of breast; non-invasive ductal carcinoma of the breast; non-invasive intraductal adenocarcinoma of breast; non-invasive ductal breast carcinoma; ductal carcinoma in situ of the breast; non-invasive ductal adenocarcinoma of the breast; intraductal breast carcinoma; intraductal carcinoma; mammary duct carcinoma in situ; non-infiltrating intraductal adenocarcinoma of the breast; non-infiltrating intraductal adenocarcinoma; non-invasive ductal breast adenocarcinoma

Definition

A carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.

Disease Hierarchy

DISSTE29: Adenocarcinoma in situ

DIS13V4C: In situ carcinoma

DISRN92I: Breast carcinoma in situ

DIS15EA5: Ductal carcinoma

DIST3WLF: Breast intraductal proliferative lesion

DISLCJY7: Ductal breast carcinoma in situ

Disease Identifiers

MONDO ID

MONDO_0005023

MESH ID

D002285

UMLS CUI

C0007124

MedGen ID

765

HPO ID

HP:0030075

SNOMED CT ID

109889007

General Information of Disease (ID: DISLCJY7)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Oxytocin	DMDL27I	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 47 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ALDH5A1	TTJUWVB	Limited	Altered Expression	[2]
CBX7	TTBN3HC	Limited	Altered Expression	[3]
DEPDC1	TT8S9CM	Limited	Altered Expression	[4]
ENPP3	TTD4TKP	Limited	Biomarker	[5]
HOXA5	TTXSVQP	Limited	Posttranslational Modification	[6]
MKI67	TTB4UNG	Limited	Biomarker	[7]
MRC2	TTYVR8M	Limited	Biomarker	[8]
PGRMC1	TTY3LAZ	Limited	Biomarker	[9]
QPCT	TTJ7YTV	Limited	Genetic Variation	[10]
RPE65	TTBOH16	Limited	Biomarker	[11]
TMPRSS2	TT1GM2Z	Limited	Biomarker	[12]
TRIM27	TTTO3QN	Limited	Biomarker	[13]
UGCG	TTPHEX3	Limited	Altered Expression	[14]
CSK	TTX6F0Q	moderate	Biomarker	[15]
CYP19A1	TTSZLWK	moderate	Biomarker	[16]
HIF1A	TTSN6QU	moderate	Altered Expression	[17]
MAP3K14	TT4LIAC	moderate	Biomarker	[18]
MUC17	TTVO0JU	moderate	Biomarker	[19]
OPRD1	TT27RFC	moderate	Genetic Variation	[20]
PTGER2	TT1ZAVI	moderate	Genetic Variation	[21]
SERPINB5	TT1KW50	moderate	Posttranslational Modification	[22]
SLC2A1	TT79TKF	moderate	Altered Expression	[17]
SNCG	TT5TQNZ	moderate	Altered Expression	[23]
TERF2	TT5XSLT	moderate	Biomarker	[24]
TIE1	TTT4236	moderate	Altered Expression	[25]
ANXA8	TTSW16P	Strong	Biomarker	[26]
CA9	TT2LVK8	Strong	Altered Expression	[17]
CTSV	TTSD9T1	Strong	Altered Expression	[27]
CUL3	TTPCU0Q	Strong	Altered Expression	[28]
DAPK3	TTERVQN	Strong	Altered Expression	[29]
INHBA	TTVB30D	Strong	Biomarker	[30]
KDM2A	TT8XTY2	Strong	Biomarker	[31]
KRT17	TTKV0EC	Strong	Biomarker	[32]
KRT19	TT3JF9E	Strong	Altered Expression	[33]
LY75	TTG180Q	Strong	Biomarker	[34]
MSMB	TTYH1ZK	Strong	Genetic Variation	[35]
NCOA4	TT8OY02	Strong	Biomarker	[36]
NEK2	TT3VZ24	Strong	Biomarker	[37]
OLFM4	TTK1CX7	Strong	Altered Expression	[38]
PGR	TTUV8G9	Strong	Biomarker	[39]
PLAC1	TTM18HX	Strong	Altered Expression	[40]
SCGB1D2	TT5D314	Strong	Biomarker	[41]
SULF2	TTLQTHB	Strong	Biomarker	[42]
ATM	TTKBM7V	Definitive	Biomarker	[43]
BRCA2	TTUARD6	Definitive	Genetic Variation	[44]
MMP11	TTZW4MV	Definitive	Biomarker	[45]
RUNX3	TTKCVO7	Definitive	Posttranslational Modification	[46]
------------------------------------------------------------------------------------


⏷ Show the Full List of 47 DTT(s)

This Disease Is Related to 5 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADH1C	DEM1HNL	Limited	Genetic Variation	[47]
ADH4	DEOCWU3	Limited	Genetic Variation	[48]
ADH5	DEIOH6A	Limited	Genetic Variation	[47]
P4HA2	DE5EGK0	moderate	Biomarker	[49]
HSD17B7	DEDMWFX	Strong	Altered Expression	[50]
------------------------------------------------------------------------------------

This Disease Is Related to 106 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADIPOR2	OT2HDTL8	Limited	Biomarker	[51]
BRMS1	OTV5A6LL	Limited	Altered Expression	[52]
CCDC112	OT3OEYG6	Limited	Biomarker	[53]
CCN5	OTADU8JJ	Limited	Altered Expression	[54]
CELSR1	OT7PS8O1	Limited	Biomarker	[55]
CKAP4	OTDUC9ME	Limited	Biomarker	[11]
CYC1	OT0962IM	Limited	Biomarker	[56]
DBT	OT4KZ5R9	Limited	Biomarker	[57]
DIRAS3	OT3XHLQA	Limited	Altered Expression	[58]
DNAJB4	OTUD01BK	Limited	Altered Expression	[59]
DOK4	OTUEWLG8	Limited	Altered Expression	[3]
FBL	OTRODIE5	Limited	Biomarker	[60]
FLOT2	OTZ0QR5L	Limited	Biomarker	[61]
GAB2	OTBFN705	Limited	Altered Expression	[62]
GALNT6	OTOQQVH1	Limited	Biomarker	[63]
GATA5	OTO81B63	Limited	Posttranslational Modification	[64]
H3-3B	OT9XHQ3C	Limited	Genetic Variation	[10]
HEATR6	OTD3MYS0	Limited	Altered Expression	[65]
NRIP1	OTIZOJQV	Limited	Altered Expression	[3]
SIAH2	OTKED2XN	Limited	Altered Expression	[66]
SLN	OTERIU75	Limited	Biomarker	[67]
SMARCE1	OTAX4ITH	Limited	Biomarker	[68]
SMR3B	OTL5HNM8	Limited	Altered Expression	[69]
TES	OTL8PP6V	Limited	Altered Expression	[70]
THOC1	OTVABJ4Z	Limited	Altered Expression	[71]
TRPS1	OT7XPPEL	Limited	Altered Expression	[72]
ADGRE2	OTUYJVYG	Disputed	Altered Expression	[73]
LPXN	OTUNV3CK	Disputed	Altered Expression	[74]
AAMP	OTZXBSS4	moderate	Altered Expression	[18]
BCS1L	OT5PY5CY	moderate	Genetic Variation	[75]
BNIP3L	OTJKOMXE	moderate	Altered Expression	[76]
CDK15	OT8S67QS	moderate	Biomarker	[18]
CDK16	OTUBXIIT	moderate	Biomarker	[18]
CILK1	OTWOYEYP	moderate	Biomarker	[18]
CST6	OTZVHJTF	moderate	Biomarker	[77]
HDLBP	OTKDEEYX	moderate	Altered Expression	[78]
IRF5	OT8SIIAP	moderate	Biomarker	[79]
KLK10	OTD573EL	moderate	Altered Expression	[80]
KPNA2	OTU7FOE6	moderate	Altered Expression	[81]
MUC3A	OTI4XUDY	moderate	Biomarker	[19]
NCOA2	OTMQFPBB	moderate	Altered Expression	[82]
NCOR1	OT04XNOU	moderate	Altered Expression	[82]
NCOR2	OTY917X0	moderate	Biomarker	[82]
OTUD4	OT7U62SW	moderate	Biomarker	[83]
PDZK1IP1	OTWA6M5K	moderate	Altered Expression	[84]
PELP1	OTVXQNOT	moderate	Altered Expression	[85]
PRKACG	OTKOQYF8	moderate	Biomarker	[18]
RAP1A	OT5RH6TI	moderate	Biomarker	[86]
SCGB3A1	OTIR98RB	moderate	Biomarker	[83]
SEMA7A	OT0ZJK64	moderate	Biomarker	[87]
SPA17	OT8J7T7U	moderate	Altered Expression	[88]
SPAG11A	OTNQ9UB0	moderate	Genetic Variation	[21]
SULF1	OTJCNCO0	moderate	Biomarker	[89]
TBPL1	OT4I143E	moderate	Biomarker	[24]
TLK1	OTICTXI8	moderate	Biomarker	[18]
ACVR1C	OTOTYERF	Strong	Altered Expression	[90]
AP2B1	OTL6LZJ4	Strong	Biomarker	[91]
ATP6AP2	OT0IABVV	Strong	Altered Expression	[92]
BCL9	OTRBIPR4	Strong	Biomarker	[93]
BNIP3	OT4SO7J4	Strong	Altered Expression	[94]
BRCA1	OT5BN6VH	Strong	Genetic Variation	[95]
COL10A1	OTC4G2YC	Strong	Biomarker	[45]
COL11A1	OTB0DRMS	Strong	Altered Expression	[96]
COL5A2	OT5VOSQE	Strong	Altered Expression	[97]
CPD	OT2CS64Y	Strong	Altered Expression	[28]
CSTA	OT1K68KE	Strong	Biomarker	[98]
ECI1	OTRQTK84	Strong	Genetic Variation	[99]
ERG	OTOTX9VU	Strong	Altered Expression	[100]
FYB1	OT6345CH	Strong	Biomarker	[101]
GTF2H2	OTK72L9I	Strong	Biomarker	[102]
HHEX	OTLIUVYX	Strong	Biomarker	[103]
IFI44	OTOKSZVA	Strong	Biomarker	[102]
INTS2	OT2N5TCK	Strong	Biomarker	[104]
KRT15	OTS6WLF7	Strong	Altered Expression	[33]
KRT81	OTMKIK2S	Strong	Biomarker	[41]
LDHB	OT9B1CT3	Strong	Biomarker	[105]
LMLN	OTQF0JPY	Strong	Genetic Variation	[35]
LPCAT1	OTCV7AGV	Strong	Altered Expression	[106]
MAP2K4	OTZPZX11	Strong	Genetic Variation	[107]
MST1	OTOC4UNG	Strong	Genetic Variation	[35]
NEU1	OTH9BY8Y	Strong	Biomarker	[108]
NEURL1	OT2C4P70	Strong	Biomarker	[108]
NRDC	OTWBBCXO	Strong	Altered Expression	[109]
NUDT2	OTMHM1DH	Strong	Biomarker	[110]
PEG10	OTWD2278	Strong	Altered Expression	[111]
POFUT1	OTOBJZIT	Strong	Altered Expression	[112]
PPP2R2B	OTSFVC82	Strong	Posttranslational Modification	[113]
PRLH	OTJBP360	Strong	Biomarker	[103]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[114]
RBM39	OTCMPTF9	Strong	Altered Expression	[92]
SFN	OTLJCZ1U	Strong	Biomarker	[26]
SIM2	OT0QWHK4	Strong	Biomarker	[115]
SNAI1	OTDPYAMC	Strong	Genetic Variation	[116]
SPAM1	OTMPOB4E	Strong	Altered Expression	[117]
SPATA18	OTOEHTHU	Strong	Biomarker	[118]
STAT5A	OTBSJGN3	Strong	Biomarker	[119]
TBX3	OTM64N7K	Strong	Altered Expression	[120]
TFAP2B	OTR1T8E9	Strong	Biomarker	[91]
TMEFF2	OT1WZ2QO	Strong	Altered Expression	[121]
TMPRSS13	OTMAOAP3	Strong	Genetic Variation	[35]
TNFAIP8L3	OTHSBS1B	Strong	Altered Expression	[122]
TRIM62	OT15YO6N	Strong	Altered Expression	[123]
ARMH1	OTTJC0D6	Definitive	Altered Expression	[124]
PI3	OT47MTC3	Definitive	Altered Expression	[125]
RABEPK	OTCZSREH	Definitive	Altered Expression	[124]
RAP1GAP	OTC31ONQ	Definitive	Biomarker	[86]
------------------------------------------------------------------------------------


⏷ Show the Full List of 106 DOT(s)

References

1	Oxytocin FDA Label
2	RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.PLoS One. 2012;7(12):e50249. doi: 10.1371/journal.pone.0050249. Epub 2012 Dec 6.
3	Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.Breast Cancer Res. 2011 Mar 4;13(2):R24. doi: 10.1186/bcr2839.
4	Identification of early molecular markers for breast cancer.Mol Cancer. 2011 Feb 11;10(1):15. doi: 10.1186/1476-4598-10-15.
5	Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.Cancer Biomark. 2013;13(3):181-92. doi: 10.3233/CBM-130337.
6	A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.Cancer Res. 2015 Sep 15;75(18):3980-90. doi: 10.1158/0008-5472.CAN-15-0506. Epub 2015 Aug 6.
7	Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.Lab Invest. 2018 Aug;98(8):1076-1083. doi: 10.1038/s41374-018-0064-1. Epub 2018 Jun 1.
8	Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.Int J Cancer. 2002 Apr 10;98(5):656-64. doi: 10.1002/ijc.10227.
9	Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging.J Surg Res. 2011 Dec;171(2):615-22. doi: 10.1016/j.jss.2010.04.034. Epub 2010 May 20.
10	Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature.Pathol Res Pract. 2020 Feb;216(2):152750. doi: 10.1016/j.prp.2019.152750. Epub 2019 Nov 19.
11	P40 Immunostain Does Not Outperform p63 as a Myoepithelial Cell Marker in the Daily Practice of Breast Pathology.Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):599-604. doi: 10.1097/PAI.0000000000000507.
12	Pathology and molecular updates in tumors of the prostate: towards a personalized approach.Expert Rev Mol Diagn. 2017 Aug;17(8):781-789. doi: 10.1080/14737159.2017.1341314. Epub 2017 Jun 15.
13	NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?.Am J Surg Pathol. 2019 Oct;43(10):1303-1313. doi: 10.1097/PAS.0000000000001301.
14	Expression of glucosylceramide synthase in invasive ductal breast cancer may be correlated with high estrogen receptor status and low HER-2 status.Diagn Pathol. 2014 Jan 23;9:22. doi: 10.1186/1746-1596-9-22.
15	Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.Br J Cancer. 2006 Nov 20;95(10):1410-4. doi: 10.1038/sj.bjc.6603444. Epub 2006 Oct 24.
16	Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.Cancer. 2017 May 15;123(6):940-947. doi: 10.1002/cncr.30425. Epub 2016 Oct 25.
17	Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.J Clin Pathol. 2020 Apr;73(4):204-208. doi: 10.1136/jclinpath-2019-206116. Epub 2019 Oct 25.
18	Analysis of gene expression in ductal carcinoma in situ of the breast.Clin Cancer Res. 2002 Dec;8(12):3788-95.
19	Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast.Breast J. 2001 Jan-Feb;7(1):40-5. doi: 10.1046/j.1524-4741.2001.007001040.x.
20	Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.Int J Cancer. 2000 Jan 1;85(1):82-6. doi: 10.1002/(sici)1097-0215(20000101)85:1<82::aid-ijc15>3.0.co;2-s.
21	Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.J Steroid Biochem Mol Biol. 2012 Nov;132(3-5):331-8. doi: 10.1016/j.jsbmb.2012.07.007. Epub 2012 Aug 19.
22	Aberrant methylation of the maspin promoter is an early event in human breast cancer.Neoplasia. 2004 Jul-Aug;6(4):380-9. doi: 10.1593/neo.04115.
23	Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing.Cancer Res. 1997 Feb 15;57(4):759-64.
24	Elevated TRF2 in advanced breast cancers with short telomeres.Breast Cancer Res Treat. 2011 Jun;127(3):623-30. doi: 10.1007/s10549-010-0988-7. Epub 2010 Jul 13.
25	Overexpression of the receptor tyrosine kinase Tie-1 intracellular domain in breast cancer.Tumour Biol. 2003 Mar-Apr;24(2):61-9. doi: 10.1159/000071078.
26	3D Mammary Epithelial Cell Models: A Goldmine of DCIS Biomarkers and Morphogenetic Mechanisms.Cancers (Basel). 2019 Jan 23;11(2):130. doi: 10.3390/cancers11020130.
27	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.J Clin Pathol. 2020 Feb;73(2):76-82. doi: 10.1136/jclinpath-2019-205939. Epub 2019 Aug 23.
28	Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.Breast Cancer Res Treat. 2017 Jul;164(1):27-40. doi: 10.1007/s10549-017-4223-7. Epub 2017 Mar 31.
29	DAPK3 suppresses acini morphogenesis and is required for mouse development.Mol Cancer Res. 2015 Feb;13(2):358-67. doi: 10.1158/1541-7786.MCR-14-0333. Epub 2014 Oct 10.
30	ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.Breast Cancer Res Treat. 2019 May;175(1):77-90. doi: 10.1007/s10549-018-05126-3. Epub 2019 Feb 6.
31	Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.PLoS One. 2014 Jul 16;9(7):e100888. doi: 10.1371/journal.pone.0100888. eCollection 2014.
32	Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.Hum Pathol. 2017 Apr;62:23-32. doi: 10.1016/j.humpath.2016.10.006. Epub 2016 Nov 2.
33	Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.Mol Oncol. 2007 Dec;1(3):321-49. doi: 10.1016/j.molonc.2007.09.004. Epub 2007 Sep 25.
34	Diagnostic utility of CD205 in breast cancer: Simultaneous detection of myoepithelial cells and dendritic cells in breast tissue by CD205.Histol Histopathol. 2020 May;35(5):481-488. doi: 10.14670/HH-18-164. Epub 2019 Sep 16.
35	Differences in Breast Cancer Characteristics by Mammography Screening Participation or Non-Participation.Dtsch Arztebl Int. 2018 Aug 6;115(31-32):520-527. doi: 10.3238/arztebl.2018.0520.
36	Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.Hum Pathol. 2019 Jan;83:50-58. doi: 10.1016/j.humpath.2018.08.011. Epub 2018 Aug 18.
37	Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer.J Cell Biochem. 2012 Jun;113(6):1904-14. doi: 10.1002/jcb.24059.
38	OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8.
39	Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer.Gynecol Endocrinol. 2019 Mar;35(3):214-216. doi: 10.1080/09513590.2018.1522298. Epub 2018 Nov 7.
40	PLAC1 as a serum biomarker for breast cancer.PLoS One. 2018 Feb 12;13(2):e0192106. doi: 10.1371/journal.pone.0192106. eCollection 2018.
41	Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.Am J Pathol. 2017 Jul;187(7):1648-1655. doi: 10.1016/j.ajpath.2017.03.012.
42	Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts.Clin Exp Metastasis. 2013 Apr;30(4):407-15. doi: 10.1007/s10585-012-9546-5. Epub 2013 Feb 15.
43	High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers.Cancer Res. 1996 Dec 1;56(23):5484-9.
44	The influence of BRCA2 mutation on localized prostate cancer.Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8.
45	Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.BMC Med Genomics. 2018 Sep 20;11(1):80. doi: 10.1186/s12920-018-0403-5.
46	An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.Oncotarget. 2017 Mar 28;8(13):22166-22174. doi: 10.18632/oncotarget.13125.
47	Impact of breast MRI in women eligible for breast conservation surgery and intra-operative radiation therapy.Surg Oncol. 2018 Mar;27(1):95-99. doi: 10.1016/j.suronc.2018.01.001. Epub 2018 Jan 8.
48	Pure flat epithelial atypia identified on core needle biopsy does not require excision.Eur J Surg Oncol. 2020 Feb;46(2):235-239. doi: 10.1016/j.ejso.2019.10.029. Epub 2019 Oct 24.
49	Prolyl-4-hydroxylase subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.
50	Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.Endocr Relat Cancer. 2008 Mar;15(1):113-24. doi: 10.1677/ERC-07-0092.
51	Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies.Endocr Relat Cancer. 2009 Dec;16(4):1197-210. doi: 10.1677/ERC-09-0043. Epub 2009 Aug 6.
52	Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model.Clin Exp Metastasis. 2009;26(2):89-96. doi: 10.1007/s10585-008-9216-9. Epub 2008 Oct 8.
53	Revisiting multifocal breast cancer: a clonality study of ductal carcinoma using whole exome sequencing.Hum Pathol. 2019 Dec;94:71-77. doi: 10.1016/j.humpath.2019.08.021. Epub 2019 Nov 6.
54	CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells.Cancer Res. 2008 Sep 15;68(18):7606-12. doi: 10.1158/0008-5472.CAN-08-1461.
55	Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).Breast Cancer Res Treat. 2016 Jun;157(3):447-59. doi: 10.1007/s10549-016-3838-4. Epub 2016 Jun 1.
56	Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.Cancer Sci. 2017 Jul;108(7):1510-1519. doi: 10.1111/cas.13251. Epub 2017 May 19.
57	Breast cancer staging: Combined digital breast tomosynthesis and automated breast ultrasound versus magnetic resonance imaging.Eur J Radiol. 2018 Oct;107:188-195. doi: 10.1016/j.ejrad.2018.09.002. Epub 2018 Sep 5.
58	Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.BMC Cancer. 2011 Jan 19;11:22. doi: 10.1186/1471-2407-11-22.
59	HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.OMICS. 2017 May;21(5):257-265. doi: 10.1089/omi.2017.0016.
60	Differential expression of follistatin and FLRG in human breast proliferative disorders.BMC Cancer. 2009 Sep 9;9:320. doi: 10.1186/1471-2407-9-320.
61	Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer.Oncogene. 2013 Oct 17;32(42):5111-22. doi: 10.1038/onc.2012.519. Epub 2012 Dec 3.
62	Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development.Int J Cancer. 2010 Sep 1;127(6):1486-92. doi: 10.1002/ijc.25172.
63	N-Acetylglucosaminyltransferase III (GnT-III) but not N-Acetylgalactosaminyltransferase-6 and 8 are Differentially Expressed in Invasive and In Situ Ductal Carcinoma of the Breast.Pathol Oncol Res. 2019 Apr;25(2):759-768. doi: 10.1007/s12253-019-00593-5. Epub 2019 Jan 28.
64	Promoter hypermethylation in ductal carcinoma in situ of the male breast.Endocr Relat Cancer. 2019 Jun;26(6):575-584. doi: 10.1530/ERC-18-0485.
65	The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ.Oncogene. 2014 Jun 5;33(23):3033-42. doi: 10.1038/onc.2013.263. Epub 2013 Jul 15.
66	The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression.Breast Cancer Res. 2011 Feb 9;13(1):R19. doi: 10.1186/bcr2828.
67	Sentinel lymph node biopsy in low risk settings.Am J Surg. 2017 Sep;214(3):489-494. doi: 10.1016/j.amjsurg.2017.03.006. Epub 2017 Mar 15.
68	SMARCE1 is required for the invasive progression of in situ cancers.Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4153-4158. doi: 10.1073/pnas.1703931114. Epub 2017 Apr 4.
69	Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.Br J Cancer. 2006 Aug 7;95(3):347-54. doi: 10.1038/sj.bjc.6603261. Epub 2006 Jul 11.
70	Testin is a tumor suppressor and prognostic marker in breast cancer.Cancer Sci. 2012 Dec;103(12):2092-101. doi: 10.1111/cas.12020. Epub 2012 Oct 22.
71	Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.J Am Coll Surg. 2005 Mar;200(3):328-35. doi: 10.1016/j.jamcollsurg.2004.10.034.
72	Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.Horm Cancer. 2010 Feb;1(1):21-33. doi: 10.1007/s12672-010-0008-8. Epub 2010 Feb 13.
73	Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival.Oncol Rep. 2011 Mar;25(3):619-27. doi: 10.3892/or.2010.1117. Epub 2010 Dec 21.
74	Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor .Int J Oncol. 2015 Jul;47(1):106-14. doi: 10.3892/ijo.2015.2988. Epub 2015 May 6.
75	Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women.Breast Cancer Res Treat. 2019 Feb;173(3):709-717. doi: 10.1007/s10549-018-5006-5. Epub 2018 Nov 8.
76	Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade.J Pathol. 2003 Dec;201(4):573-80. doi: 10.1002/path.1486.
77	Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.Breast Cancer Res. 2010;12(6):R100. doi: 10.1186/bcr2783. Epub 2010 Nov 23.
78	Phenotype of vigilin expressing breast cancer cells binding to the 69 nt 3'UTR element in CSF-1R mRNA.Transl Oncol. 2019 Jan;12(1):106-115. doi: 10.1016/j.tranon.2018.09.012. Epub 2018 Oct 3.
79	A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism.Mol Cancer. 2015 Feb 4;14(1):32. doi: 10.1186/s12943-015-0305-5.
80	Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery.Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):653-7. doi: 10.1016/s0360-3016(03)00068-3.
81	KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ.Virchows Arch. 2007 Nov;451(5):877-81. doi: 10.1007/s00428-007-0513-5. Epub 2007 Sep 27.
82	Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.Clin Cancer Res. 2000 Feb;6(2):512-8.
83	Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis.Cancer Biol Ther. 2008 Sep;7(9):1398-406. doi: 10.4161/cbt.7.9.6425. Epub 2008 Sep 4.
84	Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique.Clin Cancer Res. 1995 Oct;1(10):1209-15.
85	Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.Cancer Res. 2007 Jun 1;67(11):5505-12. doi: 10.1158/0008-5472.CAN-06-3647.
86	Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.Neoplasia. 2018 Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002. Epub 2018 Aug 22.
87	Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression.Oncogene. 2016 Sep 29;35(39):5170-8. doi: 10.1038/onc.2016.49. Epub 2016 Apr 11.
88	Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer.Front Oncol. 2019 Jul 31;9:710. doi: 10.3389/fonc.2019.00710. eCollection 2019.
89	Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.
90	Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.Med Oncol. 2012 Dec;29(4):2519-26. doi: 10.1007/s12032-011-0114-7. Epub 2011 Nov 16.
91	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2.Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.
92	CAPER, a novel regulator of human breast cancer progression.Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.
93	Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.
94	BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):467-74. doi: 10.1158/1078-0432.CCR-06-1466.
95	BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16.
96	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.Mod Pathol. 2019 Oct;32(10):1460-1472. doi: 10.1038/s41379-019-0286-9. Epub 2019 Jun 7.
97	Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.Breast Cancer Res Treat. 2012 Aug;135(1):153-65. doi: 10.1007/s10549-012-2123-4. Epub 2012 Jun 21.
98	Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.
99	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.
100	The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.Prostate. 2019 Jun;79(8):819-825. doi: 10.1002/pros.23785. Epub 2019 Mar 22.
101	Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma.J Int Med Res. 2020 Jan;48(1):300060518815364. doi: 10.1177/0300060518815364. Epub 2019 Feb 3.
102	Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion.J Cell Mol Med. 2010 Dec;14(12):2780-9. doi: 10.1111/j.1582-4934.2009.00936.x.
103	Proline-Rich Homeodomain protein (PRH/HHEX) is a suppressor of breast tumour growth.Oncogenesis. 2017 Jun 12;6(6):e346. doi: 10.1038/oncsis.2017.42.
104	Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction.Int J Mol Med. 2001 Aug;8(2):193-8. doi: 10.3892/ijmm.8.2.193.
105	Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. doi: 10.1371/journal.pone.0057697. Epub 2013 Feb 21.
106	Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.Tumour Biol. 2015 Jul;36(7):5473-83. doi: 10.1007/s13277-015-3214-8. Epub 2015 Feb 16.
107	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24.
108	Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.Am J Surg Pathol. 2019 Sep;43(9):1221-1228. doi: 10.1097/PAS.0000000000001300.
109	Elevated NRD1 metalloprotease expression plays a role in breast cancer growth and proliferation.Genes Chromosomes Cancer. 2011 Oct;50(10):837-47. doi: 10.1002/gcc.20905. Epub 2011 Jul 18.
110	Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer. 2011 Apr 15;128(8):1770-82. doi: 10.1002/ijc.25505.
111	Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.Clin Exp Metastasis. 2018 Feb;35(1-2):3-13. doi: 10.1007/s10585-017-9868-4. Epub 2017 Dec 6.
112	Overexpression of Pofut1 and activated Notch1 may be associated with poor prognosis in breast cancer.Biochem Biophys Res Commun. 2017 Sep 9;491(1):104-111. doi: 10.1016/j.bbrc.2017.07.053. Epub 2017 Jul 11.
113	Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 2010;12(1):R3.
114	BRCA2 carriers with male breast cancer show elevated tumour methylation.BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.
115	ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition.Oncogene. 2019 Apr;38(14):2611-2626. doi: 10.1038/s41388-018-0622-4. Epub 2018 Dec 10.
116	Biological Aggressiveness of Subclinical No-Mass Ductal Carcinoma In Situ (DCIS) Can Be Reflected by the Expression Profiles of Epithelial-Mesenchymal Transition Triggers.Int J Mol Sci. 2018 Dec 7;19(12):3941. doi: 10.3390/ijms19123941.
117	Expression of PH-20 in normal and neoplastic breast tissue.J Surg Res. 2002 Apr;103(2):203-7. doi: 10.1006/jsre.2002.6351.
118	Possible role of p53/Mieap-regulated mitochondrial quality control as a tumor suppressor in human breast cancer.Cancer Sci. 2018 Dec;109(12):3910-3920. doi: 10.1111/cas.13824. Epub 2018 Nov 2.
119	Possible role of Stat5a in rat mammary gland carcinogenesis.Breast Cancer Res Treat. 2004 Dec;88(3):263-72. doi: 10.1007/s10549-004-0805-2.
120	TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.J Pathol. 2019 Jun;248(2):191-203. doi: 10.1002/path.5245. Epub 2019 Apr 8.
121	Promoter CpG island hypermethylation during breast cancer progression.Virchows Arch. 2011 Jan;458(1):73-84. doi: 10.1007/s00428-010-1013-6. Epub 2010 Dec 1.
122	TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-B signaling pathways.Oncotarget. 2017 Jul 25;8(30):48889-48904. doi: 10.18632/oncotarget.16522.
123	DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.PLoS Med. 2009 May 26;6(5):e1000068. doi: 10.1371/journal.pmed.1000068. Epub 2009 May 5.
124	Evaluation of p40 as a Myoepithelial Marker in Different Breast Lesions.Pathobiology. 2015 Sep;82(3-4):166-71. doi: 10.1159/000375127. Epub 2015 Aug 31.
125	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.Breast Cancer Res. 2014;16(6):3417. doi: 10.1186/s13058-014-0497-4.